JPS55135590A - Modified asparaginase and uricase and their preparation - Google Patents

Modified asparaginase and uricase and their preparation

Info

Publication number
JPS55135590A
JPS55135590A JP4120379A JP4120379A JPS55135590A JP S55135590 A JPS55135590 A JP S55135590A JP 4120379 A JP4120379 A JP 4120379A JP 4120379 A JP4120379 A JP 4120379A JP S55135590 A JPS55135590 A JP S55135590A
Authority
JP
Japan
Prior art keywords
uricase
asparaginase
polyethylene glycol
high polymer
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP4120379A
Other languages
Japanese (ja)
Other versions
JPS6142558B2 (en
Inventor
Yuji Inada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIHAMA HISAHARU
Original Assignee
MIHAMA HISAHARU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIHAMA HISAHARU filed Critical MIHAMA HISAHARU
Priority to JP4120379A priority Critical patent/JPS55135590A/en
Publication of JPS55135590A publication Critical patent/JPS55135590A/en
Publication of JPS6142558B2 publication Critical patent/JPS6142558B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURPOSE: To prevent the reduction of enzyme activity, to lower the antigenicity, and to improve the safety as drugs, the reacting L-asparaginase or uricase with a triazine having a double helix water-souble high polymer residue.
CONSTITUTION: L-asparaginase or uricase is reacted with a 2, 4-bis (O-substituted- polyethylene glycol)-6-chloro-S-triazine having a molecular weight not less than 2,000 to give a modified asparaginase or uricase wherein amino group in the molecule is replaced partly by a group shown by the formula (R is a water-soluble high polymer) residue having a molecular weight not less than 2,000). Residues of polyethylene glycol, polyvinyl-alcohol, polyvinyl pyrrolidone, etc. may be cited as the water-soluble high polymer residue, and especially polyethylene glycol.
COPYRIGHT: (C)1980,JPO&Japio
JP4120379A 1979-04-05 1979-04-05 Modified asparaginase and uricase and their preparation Granted JPS55135590A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4120379A JPS55135590A (en) 1979-04-05 1979-04-05 Modified asparaginase and uricase and their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4120379A JPS55135590A (en) 1979-04-05 1979-04-05 Modified asparaginase and uricase and their preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP61093855A Division JPS6255079A (en) 1986-04-23 1986-04-23 Modified uricase

Publications (2)

Publication Number Publication Date
JPS55135590A true JPS55135590A (en) 1980-10-22
JPS6142558B2 JPS6142558B2 (en) 1986-09-22

Family

ID=12601850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4120379A Granted JPS55135590A (en) 1979-04-05 1979-04-05 Modified asparaginase and uricase and their preparation

Country Status (1)

Country Link
JP (1) JPS55135590A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460683A (en) * 1981-07-07 1984-07-17 Boehringer Mannheim Gmbh Soluble liver uricase with a process for the preparation thereof and with the use thereof
JPS62175175A (en) * 1986-01-28 1987-07-31 Mihama Hisaharu Modified tryptophanase and production thereof
JP2002522399A (en) * 1998-08-06 2002-07-23 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Peg-uric acid oxidase conjugates and uses thereof
US7723089B2 (en) 1998-08-06 2010-05-25 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US7927852B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US9926537B2 (en) 2005-04-11 2018-03-27 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5515224B2 (en) 2007-02-28 2014-06-11 日油株式会社 Multi-branched polyoxyalkylene derivatives

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460683A (en) * 1981-07-07 1984-07-17 Boehringer Mannheim Gmbh Soluble liver uricase with a process for the preparation thereof and with the use thereof
JPS62175175A (en) * 1986-01-28 1987-07-31 Mihama Hisaharu Modified tryptophanase and production thereof
US9885024B2 (en) 1998-08-06 2018-02-06 Duke University PEG-urate oxidase conjugates and use thereof
JP2002522399A (en) * 1998-08-06 2002-07-23 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド Peg-uric acid oxidase conjugates and uses thereof
US7927852B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US7927589B2 (en) 1998-08-06 2011-04-19 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US8067553B2 (en) 1998-08-06 2011-11-29 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US8618267B2 (en) 1998-08-06 2013-12-31 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US8921064B2 (en) 1998-08-06 2014-12-30 Mountain View Pharmaceuticals, Inc. Method for purifying urate oxidase tetramers and octamers
US7723089B2 (en) 1998-08-06 2010-05-25 Mountain View Pharmaceuticals, Inc. PEG-urate oxidase conjugates and use thereof
US9926537B2 (en) 2005-04-11 2018-03-27 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US9926538B2 (en) 2005-04-11 2018-03-27 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10160958B2 (en) 2005-04-11 2018-12-25 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US10731139B2 (en) 2005-04-11 2020-08-04 Horizon Pharma Rheumatology Llc Variant forms of urate oxidase and use thereof
US11345899B2 (en) 2005-04-11 2022-05-31 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US11781119B2 (en) 2005-04-11 2023-10-10 Horizon Therapeutics Usa, Inc. Variant forms of urate oxidase and use thereof
US9534013B2 (en) 2006-04-12 2017-01-03 Horizon Pharma Rheumatology Llc Purification of proteins with cationic surfactant
US10139399B2 (en) 2009-06-25 2018-11-27 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US10823727B2 (en) 2009-06-25 2020-11-03 Horizon Pharma Rheumatology Llc Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11598767B2 (en) 2009-06-25 2023-03-07 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
US11639927B2 (en) 2009-06-25 2023-05-02 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
US11982670B2 (en) 2009-06-25 2024-05-14 Horizon Therapeutics Usa, Inc. Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy

Also Published As

Publication number Publication date
JPS6142558B2 (en) 1986-09-22

Similar Documents

Publication Publication Date Title
AU8989891A (en) Novel 5-chloroquinolin-8-oxyalkanecarboxylic acid derivatives, processes for their preparation and their use as antidotes for herbicides
AU587897B2 (en) Preparation of solid pharmaceutical forms
PH31617A (en) Novel thienylcarboxylates of amino alcohols, theirquaternary products and use of these compounds.
MY101847A (en) Composition for solid pharmaceutical preparations of active vitamins d 3 and process for preparation thereof.
DE3766200D1 (en) L-DOPA CONTAINING MEDICINAL PRODUCT.
JPS55135590A (en) Modified asparaginase and uricase and their preparation
MY109366A (en) Polysuccinimide polymers and process for preparing polysuccinimide polymers
EP0230574A3 (en) Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
CA2165306A1 (en) Fuel additive compositions containing an aliphatic amine, a polyolefin and a poly(oxyalkylene) monool
WO1991015512A3 (en) Hiv envelope polypeptides
EP0369752A3 (en) Preparation process of polyoxyalkylene polyamine having terminal secondary amino group
JPS5599189A (en) Modified uricase free from antigenicity and its preparation
EP0253143A3 (en) Pharmaceutical compositions for suppository
EP0268090A3 (en) Polyetherimide esters
ES8802579A1 (en) Rinse aid composition
CA2027341A1 (en) Process for the preparation of 3-(l-pyroglutamyl)-l-thiazolidine-4-carboxylic acid and its derivatives
IL108997A0 (en) Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
JPS6438031A (en) Aids remedy
EP0208785A4 (en) Fibrinophilic urokinase complex and process for its preparation.
IE890076L (en) Porhpyric insecticides
CA2085221A1 (en) Phosphoroustrislactams and methods for their production
HU892527D0 (en) Process for producing of low molecular weight prourochinase derivatives and manufacturing of pharmaceutical compositions comprising them as active ingredients
JPS5438389A (en) Preparation of highly crystalline polyolefin
EP0138784A3 (en) Arabinogalactans, their preparation and compositions containing same
Filgueiras Grasses and herbivores- considerations on the coevolutionary process.